Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from March 24, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on June 22, 2026 — +24.7% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$35.50 – $37.50Entry zone — fair-value band

$36.80Published — price the day we called it

$43.06Target — the price the thesis aimed for

$47.79Peak — highest point inside the window, not a realized return

$45.88Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 38 days.

At window close

+24.7%

realized, from the publication price to the last close inside the window

Peak gain

+29.9%

peak, from the publication price — not a realized return

S&P 500, same window

+14.3%

SPY over the identical days, dividend-adjusted

Window close

$45.88

last close inside the window, ended June 22, 2026

Peak price

$47.79

peak on May 11, 2026 — not a realized return

Days to target

The thesis — published March 24, 2026

Predicted growth

+17%

over the measurement window

Target price

$43.06

the price the thesis aimed for

Entry zone

$35.50 – $37.50

the fair-value band we waited for

Price at publication

$36.80

published March 24, 2026

Confidence

82%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Shares look positioned to recover over the next few months because prices fell sharply and the company now has a clear, positive product development-approval of a higher-dose Wegovy-and more obesity treatments coming. The business combines steady healthcare characteristics, reasonable valuation, and upside if investor mood improves, though recent operating trends were uneven.

Primary drivers

Higher-dose Wegovy approval boosts the obesity treatment story
New drugs in the pipeline keep the company a leader in obesity care
Recent share drop creates room for a rebound if sentiment steadies
Large-cap healthcare tends to be more stable than high-growth names

How it played out

NVO: target reached in 38 days

Lyra published NVO at 36.80 with expected growth of 17%. The thesis pointed to higher-dose Wegovy approval, more obesity treatments in the pipeline, room for a rebound after the share drop, and the relative stability of large healthcare companies. It also noted uneven recent operating trends.

The price reached the 43.06 target in 38 days. It later peaked at 47.79 on May 11, a gain of 29.9%. NVO ended the window at 45.88, still above the target. The published thesis played out.

What happened during the window

On May 6, 2026, Novo Nordisk reported that adjusted first-quarter sales fell 4% at constant exchange rates, while adjusted obesity care sales rose 22%. On May 22, 2026, the company announced that a European regulator's committee had recommended Wegovy 7.2 mg for approval.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals